iRhythm closes offering worth more than $660M

San Francisco-based cardiac monitor maker iRhythm Technologies has successfully concluded an offering of senior notes, amassing gross proceeds totaling $661.25 million. Originally slated at $450 million, the offering was quickly expanded to a base of $575 million within 17 hours. 

The notes, maturing on September 1, 2029, were sold to qualified institutional buyers and include an additional $86.25 million option. iRhythm anticipates net proceeds of approximately $643 million, accounting for initial purchaser discounts and estimated offering expenses. The company allocated a portion of the funds to cover capped call transactions, repay outstanding debt, and repurchase shares of its common stock. The remainder will be utilised for general corporate purposes, encompassing activities like sales and marketing, research and development, and potential investments or acquisitions.

The senior notes, now obligations of iRhythm, carry semi-annual interest payments and provide the option for holders to require the company to repurchase the notes at 100% of their principal amount, plus interest. With a maturity date of September 1, 2029, the notes may be converted, repurchased, or redeemed before that date. iRhythm's strategic use of the funds includes addressing various financial obligations, supporting ongoing operations, and potentially fueling future investments or acquisitions, though no specific plans have been outlined at this time. The successful offering reflects investor confidence in iRhythm's position in the cardiac monitoring sector and its strategic plans for growth and development.